Tumour suppressor p53 inhibits hepatitis C virus replication by inducing E6AP-mediated proteasomal degradation of the viral core protein

FEBS Lett. 2022 Oct;596(19):2525-2537. doi: 10.1002/1873-3468.14461. Epub 2022 Aug 8.

Abstract

The tumour suppressor p53 has been implicated in the host defence system against hepatitis C virus (HCV) infection, although the detailed mechanism remains unknown. Here, we found that p53 inhibits HCV replication by downregulating HCV Core protein levels in human hepatoma cells. For this effect, p53 potentiated the role of E6-associated protein (E6AP) as an E3 ligase to induce ubiquitination and proteasomal degradation of HCV Core. Specifically, p53 facilitated the binding of E6AP to HCV Core through direct interactions with the two proteins. In addition, E6AP failed to induce ubiquitination of HCV Core in the absence of p53, suggesting that p53 increases the E3 ligase activity of E6AP in a triple complex consisting of p53, E6AP and HCV Core.

Keywords: E6-associated protein; core; hepatitis C virus; p53; ubiquitination.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Hepacivirus / metabolism
  • Hepatitis C*
  • Humans
  • Neoplasms*
  • Oncogene Proteins, Viral* / metabolism
  • Proteasome Endopeptidase Complex / metabolism
  • Tumor Suppressor Protein p53 / metabolism
  • Ubiquitin-Protein Ligases / genetics
  • Ubiquitin-Protein Ligases / metabolism
  • Viral Core Proteins / metabolism
  • Virus Replication

Substances

  • Oncogene Proteins, Viral
  • Tumor Suppressor Protein p53
  • Viral Core Proteins
  • Ubiquitin-Protein Ligases
  • Proteasome Endopeptidase Complex